Eli Lilly’s Mounjaro receives FDA approval to lower cardiovascular risk; Teva announces acquisition of approved drug

Eli Lilly’s once‑a‑diabetes blockbuster tirzepatide, marketed as Mounjaro, was granted FDA approval on Friday for an indication that reduces the risk of major cardiovascular events.

The approval expands the drug’s label beyond glucose control, offering physicians a new tool to manage patients at high heart‑disease risk while leveraging the drug’s existing market presence.

Separately, Teva Pharmaceutical announced it will purchase an already approved medication, adding another asset to its portfolio. The brief also referenced updates from AusperBio and Samsung Biologics, though details were not provided.